A drug can spend years being hurried from room to room. A toxicology lab tests it. A formulation group turns it into something a person can take. A manufacturer makes the clinical batch. A clinic gives it to volunteers. A bioanalytical team measures what happened. Every specialist may be excellent, yet the molecule still loses weeks in email, contracting, file transfers and the strangely expensive sentence, “Can you bring the next vendor up to speed?”
Altasciences built its modern business around that sentence. The Laval, Quebec company is an integrated CRO/CDMO - industry shorthand for a contract research organization joined to a contract development and manufacturing organization. It works for biotech and pharmaceutical sponsors from lead-candidate selection through preclinical safety studies, formulation, early clinical trials, bioanalysis and proof of concept. Sponsors can buy one service. The more interesting offer is the whole relay race, with fewer baton passes.
The First Thing That Failed Was the Old Math
This was not the original plan. The company grew from Algorithme Pharma, a Montreal-area research business founded in the early 1990s and inaugurated as a CRO in 1995. It built a clinical site and bioanalytical laboratory in 1996, won a first U.S. biotech contract in 1999 and passed its first U.S. Food and Drug Administration inspection in 2001. Its base, however, was generic-drug testing - useful work with the economics of a tightening vise.
When Chris Perkin became chief executive in 2010, management could see price and volume pressure weakening that model. That was the mind-changing fact. The company did not wait for the core to collapse. It moved toward novel drug development, where a sponsor values judgment, coordination and speed to a financing or regulatory milestone, not merely the lowest price for a test.
“Before 2010, Altasciences was built on the generic industry, but we saw the negative impact that price and volume were going to play.”Chris Perkin, former CEO
The pivot arrived as a sequence of physical bets. In 2013, the company took the Altasciences name and bought Vince & Associates Clinical Research in Kansas City. Preclinical safety capacity arrived in Seattle in 2018. The 2020 purchase of Alliance Contract Pharma added formulation, analytical services and manufacturing near Philadelphia. Clinical capacity in Los Angeles and preclinical operations in Scranton followed in 2021; Columbia, Missouri and Sacramento joined in 2022. Audax Private Equity backed part of this expansion from 2017, then sold Altasciences to Novo Holdings in 2021. The prices of those transactions were not disclosed.
What the Customer Actually Buys
The customer is not a patient, though patients ultimately sit at the end of the chain. It is usually a biotech or pharmaceutical team with an experimental molecule, a finite cash runway and a list of questions regulators will expect it to answer. Is the candidate safe enough to enter humans? Can it be manufactured consistently? What dose reaches the bloodstream? Does a biological signal appear? Is there enough evidence to continue, change the formulation or stop?
Altasciences sells the labor and infrastructure needed to answer those questions: GLP and non-GLP toxicology, clinical pharmacology from first-in-human studies through Phase II, small- and large-molecule bioanalysis, biomarkers and immunogenicity, drug formulation, clinical supply, stability testing, medical writing, regulatory strategy, data management and biostatistics. In plain English, it can test a molecule in the lab, make a usable version, run an early human study and package the resulting evidence.
The business model is contract work. A sponsor requests a proposal for a stand-alone study, a bundle of services, a full program or dedicated staff. There is no public menu price because modality, species, assay, batch, population and protocol can change the scope dramatically. The honest answer to “what did it cost?” is therefore: project pricing and acquisition terms are private. The economic promise is not a cheap line item. It is fewer paid delays and earlier go-or-no-go decisions.
The Product Between the Products
Altasciences' differentiator is not that nobody else owns labs, clinics or factories. Large rivals including Charles River, Labcorp and Thermo Fisher's PPD business cover broad portions of the same market. Smaller specialists can go deeper in a narrow assay or modality. Altasciences sits between them: large enough to connect the early-development chain, small enough to pitch attention and flexibility.
Its real product is connective tissue. The company calls the communication idea “Tell Us Once” and assigns a cross-functional program manager as the sponsor's main contact. Central scheduling is meant to let formulation and manufacturing proceed alongside safety work when the protocol allows, while data moves directly into clinical planning and regulatory documents. The company says this can remove 25 to 40 percent of development time. Former CEO Perkin described it more bluntly as cutting waste without accelerating any individual regulated process.
That distinction matters. Faster drug development can sound like a corner-cutting contest. In a regulated system, the more defensible gain comes from starting compatible work earlier, designing assays with downstream needs in mind and preventing a team from reconstructing context at every vendor boundary. Altasciences is selling a faster organization around science that still has to meet the same standards.
Copy the Coordination, Not the Buying Spree
Founders and service operators can steal this playbook without acquiring a toxicology lab. Start with the customer's calendar, not your org chart. Mark every place information is repeated, ownership changes or work waits for a previous team to finish. Then give one person authority across that journey and measure elapsed time between deliverables, not simply utilization inside each department.
The part worth stealing
- Find the handoff customers complain about after the invoice is paid.
- Bundle adjacent work only where shared context produces a real advantage.
- Give one operator responsibility for the end-to-end outcome.
- Turn saved calendar time into a visible, testable promise.
- Keep stand-alone service available for customers who value choice.
Altasciences has also begun layering software and partnerships onto the physical network. A 2025 collaboration with Evidence Matters targets regulatory writing and document workflows; a 2026 proof of concept extended that work into nonclinical automation. A partnership with Certara adds model-informed drug development. VoxCell BioInnovation brings 3D-bioprinted tissue models to selected preclinical questions. These are sensible extensions because each one attacks an information gap around the core laboratory work.
Where the Model Stops Working
Integration is useful, not mystical. A sponsor needing one specialized assay may get no benefit from the wider platform. A late-stage, multinational Phase III program sits beyond Altasciences' early-phase center of gravity. A novel modality may demand a specialist with equipment or experience the network lacks. Procurement teams may also prefer separate vendors to preserve leverage, compare results or limit concentration risk.
A small or mid-sized sponsor needs several adjacent early-phase services, values one accountable operator and will share data early enough for parallel planning.
The job is isolated, late-stage or unusually specialized; independence between vendors matters; or internal teams will not let the provider coordinate the full program.
There is a cultural risk, too. A company can buy an integrated map and still operate as a federation of acquired silos. Altasciences publicly emphasizes customer focus, quality, integrity, respect and employee development. Its career page presents a fast-paced, collaborative workplace; anonymous employee reviews are less uniform, particularly around workload, pay and management. The integration promise depends on people behaving as one team, which is harder than drawing five boxes under one logo.
The next test belongs to Marie-Hélène Raigneau, who became chief executive in February 2026 after serving as president. Perkin moved to Executive Chairman after a planned transition. Raigneau inherits a company that has already made the big strategic turn. Her job is less cinematic and probably more difficult: make nine cities and more than 2,200 employees feel like one operating system to a biotech client with two molecules and no time to waste.
That is Altasciences' place in the market. It is neither a single-purpose lab nor a globe-spanning late-stage trial machine. It is an early-development platform built around a practical observation: molecules do not experience an org chart, but schedules do. The bet is that operational patience can become scientific speed without confusing haste for progress. Remove enough seams, and the customer gets the only result that matters before approval - a better answer, sooner.